Navigation Links
Indevus Pharmaceuticals Announces Release of 2008 Annual Report
Date:1/27/2009

LEXINGTON, Mass., Jan. 27 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that a copy of its 2008 Annual Report has been posted on and is available at the Company's website at www.indevus.com. In addition, the Company's stockholders may obtain a free hard copy of the Annual Report by contacting the Company's Investor Relations department at (781) 861-8444 or by mailing written requests to Indevus Pharmaceuticals, Inc., Attention Investor Relations, 33 Hayden Ave., Lexington, Massachusetts 02421.

The Company's common stock is listed and traded on the NASDAQ Global Market under the symbol "IDEV."

About Indevus Pharmaceuticals

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. 

    Contact:
    Michael W. Rogers
    EVP and Chief Financial Officer
    (781) 861-8444

    Robin L. DeCarlo
    Sr. Director, Corporate Communications
    (781) 402-3405


'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1

Related biology technology :

1. Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results
2. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
3. Indevus and FDA Agree on Path Forward for NEBIDO(R)
4. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
5. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
6. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
7. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
8. Indevus Announces Management Changes
9. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
10. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
11. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , NOVATO, Calif., Nov. 30 /PRNewswire-Firs...MRN ) announced today that the Food and Drug Admin...n for 3,4-diaminopyridine (3,4-DAP), amifampridine...t Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has p...E.U. Also, in October 2009, the Committee for Med...
(Date:11/30/2009)..., , BOSTON and COPENHAGEN, Nov. 30 /PRNew...) announced today that the Harvard Medical School ... recognized as a MicroRNA Screening Center of Exce...Medical School, and associated hospitals and insti...lecule and RNAi libraries. ,, MicroRNAs are a n...
(Date:11/30/2009)..., , AMSTERDAM,...he world,s,leading publisher of scientific, medica...nced a major re-launch of Embase, its comprehensiv...indexed records from more than 7,000,active, peer ...ed a key role in the advancement of new biomedical...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswire...k, will initiate water-soluble carbon nanotube-bas.... The water-soluble carbon nanotubes, which have f...ugation with cancer drugs, was developed in partne...he conjugated carbon nanotubes serves as a drug de...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...assay for inhibition of poly(ADP-ribose) polymeras...es the inhibition of PARP-activated incorporation ...NAD). The incorporation is detected using Europium...way to screen test compounds for PARP activity in ...reening. , Poly(ADP-ribose) polymerase (PA...
...ts (QDs) have potential applications, ...emory devices, and sources of laser ..., herein to possess a nonlinear change ...correlated to size and composition, as monitored b...pectrofluorometer. The QDs, emission wavelength,...
... Many companies claim high sensitivity for their ...rument vendors often cite excitation of de-ionized...at 397 nm (an energy loss of 3380 cm 1 ). This Ram...nal is red-shifted and weak, thus mimicking weak f...making sample-to-sample reproducibility straightfo...
Other Biology Technology:A DELFIA Assay for Inhibition of PARP 2A DELFIA Assay for Inhibition of PARP 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 2Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 3Photoluminescence Spectroscopy of Quantum Dots, monitored by the Spex FluoroMax 4Wideband sensitivity of the FluoroLog-3 2
(Date:12/1/2009)...s an ,abominable mystery, and it is a question whi... when did flowering plants evolve and how did they...dy in Ecology Letters reveals the evolutionary t... a major competitive advantage over rival species,..., The study, by Dr Tim Brodribb and Dr Taylor Fi...
(Date:11/30/2009)... review of the state of Antarctica,s climate and i...blished this week (Tuesday 1 December) by the Scie...e review - Antarctic Climate Change and the Enviro...ontinent, identifies areas for future scientific r...olicy makers have about Antarctic melting, sea-lev...
(Date:11/30/2009)...of Pittsburgh team overcame a major hurdle plaguin...hat could lead to more efficient catalysts used to...c. The researchers reported Nov. 29 in Nature Mat...e stability in metallic nanoparticles, the vaunted...lity to extreme heat. , Gtz Veser, an associate ...
Breaking Biology News(10 mins):How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2First metallic nanoparticles resistant to extreme heat 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 1Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 3Iowa Drug Card a Huge Success With Iowans 55345 1Iowa Drug Card a Huge Success With Iowans 55345 2Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 1Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 2
... MADISON Pfizer Inc., a major biopharmaceutical ...ion (WARF), the private, nonprofit patenting and l...sin-Madison, announced May 5 that they have signed...ents for the development of new drug therapies. , ...rk with hES cells for drug research and discovery....
... , An effort is under way at the University of Hou...obile industry to develop new tools that will help...rapy for patients with head and neck cancer. , Dr... Free Form Fabrication Laboratory at UH and a form.... Lei Dong, associate professor and deputy researc...
... The National Center for Research Resources (NCRR...unced today it will provide up to an estimated $12...tional Development Award (IDeA) Networks of Biomed...gible states. By promoting the development, coordi...tise, these awards expand research opportunities a...
Other Biology News:WARF signs license agreement with Pfizer for human embryonic stem cells 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 2From cars to cancer: UH professor employs auto industry tools for tumor therapy 3From cars to cancer: UH professor employs auto industry tools for tumor therapy 4NIH grants $122 million in Institutional Development Awards 2NIH grants $122 million in Institutional Development Awards 3
Anti-IRS 2, phospho (Ser731) Polyclonal Antibody, Unconjugated from BioSource International (Invitrogen)
... for non-denaturing polyacrylamide and agarose gel... solution contains a bromophenol blue tracking dye...loading. EDTA has been included to inhibit nucleas...added to help dissociate DNA-protein complexes whi...
Gel Loading Solution (Type I) from Sigma-Aldrich
Mouse Anti-Human QPRT Polyclonal Antibody, Unconjugated from Novus Biologicals
Biology Products: